1. Product Overview
2. Research Methodology
3. Impact of COVID-19
on Global Formulation Development Outsourcing Market
4. Voice of Customer
5. Executive Summary
6. Global Formulation
Development Outsourcing Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Services (Pre-Formulation
Services v/s Formulation Optimization)
6.2.1.1.
By Pre-Formulation Services (Discovery & Preclinical Services v/s
Analytical Services)
6.2.1.2.
By Formulation Optimization (Phase I, Phase II, Phase III, Phase IV)
6.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
6.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
6.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
6.2.5. By Region
6.2.6. By
Company (2020)
6.3.
Product Market Map
7. North America Formulation
Development Outsourcing Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Services
(Pre-Formulation Services v/s Formulation Optimization)
7.2.1.1.
By Pre-Formulation Services (Discovery & Preclinical Services v/s
Analytical Services)
7.2.1.2.
By Formulation Optimization (Phase I, Phase II, Phase III, Phase IV)
7.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
7.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
7.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
7.2.5.
By Country
7.3.
North America: Country Analysis
7.3.1.
United States Formulation Development Outsourcing Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Services
7.3.1.2.2.
By Dosage Form
7.3.1.2.3.
By Application
7.3.1.2.4.
By End User
7.3.2.
Mexico Formulation Development Outsourcing Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Services
7.3.2.2.2.
By Dosage Form
7.3.2.2.3.
By Application
7.3.2.2.4.
By End User
7.3.3.
Canada Formulation Development Outsourcing Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Services
7.3.3.2.2.
By Dosage Form
7.3.3.2.3.
By Application
7.3.3.2.4.
By End User
8. Europe Formulation
Development Outsourcing Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Services
(Pre-Formulation Services v/s Formulation Optimization)
8.2.1.1.
By Pre-Formulation Services (Discovery & Preclinical Services v/s
Analytical Services)
8.2.1.2.
By Formulation Optimization (Phase I, Phase II, Phase III, Phase IV)
8.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
8.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
8.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
8.2.5.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Formulation Development Outsourcing Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Services
8.3.1.2.2.
By Dosage Form
8.3.1.2.3.
By Application
8.3.1.2.4.
By End User
8.3.2.
United Kingdom Formulation Development Outsourcing Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Services
8.3.2.2.2.
By Dosage Form
8.3.2.2.3.
By Application
8.3.2.2.4.
By End User
8.3.3.
Italy Formulation Development Outsourcing Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Services
8.3.3.2.2.
By Dosage Form
8.3.3.2.3.
By Application
8.3.3.2.4.
By End User
8.3.4.
Germany Formulation Development Outsourcing Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Services
8.3.4.2.2.
By Dosage Form
8.3.4.2.3.
By Application
8.3.4.2.4.
By End User
8.3.5.
Spain Formulation Development Outsourcing Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Services
8.3.5.2.2.
By Dosage Form
8.3.5.2.3.
By Application
8.3.5.2.4.
By End User
9. Asia-Pacific Formulation
Development Outsourcing Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Services
(Pre-Formulation Services v/s Formulation Optimization)
9.2.1.1.
By Pre-Formulation Services (Discovery & Preclinical Services v/s
Analytical Services)
9.2.1.2.
By Formulation Optimization (Phase I, Phase II, Phase III, Phase IV)
9.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
9.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
9.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
9.2.5.
By Country
9.3.
Asia-Pacific: Country Analysis
9.3.1.
China Formulation Development Outsourcing Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Services
9.3.1.2.2.
By Dosage Form
9.3.1.2.3.
By Application
9.3.1.2.4.
By End User
9.3.2.
India Formulation Development Outsourcing Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Services
9.3.2.2.2.
By Dosage Form
9.3.2.2.3.
By Application
9.3.2.2.4.
By End User
9.3.3.
Japan Formulation Development Outsourcing Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Services
9.3.3.2.2.
By Dosage Form
9.3.3.2.3.
By Application
9.3.3.2.4.
By End User
9.3.4.
South Korea Formulation Development Outsourcing Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Services
9.3.4.2.2.
By Dosage Form
9.3.4.2.3.
By Application
9.3.4.2.4.
By End User
9.3.5.
Australia Formulation Development Outsourcing Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Services
9.3.5.2.2.
By Dosage Form
9.3.5.2.3.
By Application
9.3.5.2.4.
By End User
10. South America Formulation
Development Outsourcing Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Services
(Pre-Formulation Services v/s Formulation Optimization)
10.2.1.1. By Pre-Formulation
Services (Discovery & Preclinical Services v/s Analytical Services)
10.2.1.2. By Formulation
Optimization (Phase I, Phase II, Phase III, Phase IV)
10.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
10.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
10.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
10.2.5.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Formulation Development Outsourcing Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Services
10.3.1.2.2.
By Dosage Form
10.3.1.2.3.
By Application
10.3.1.2.4.
By End User
10.3.2.
Argentina Formulation Development Outsourcing Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Services
10.3.2.2.2.
By Dosage Form
10.3.2.2.3.
By Application
10.3.2.2.4.
By End User
10.3.3.
Colombia Formulation Development Outsourcing Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Services
10.3.3.2.2.
By Dosage Form
10.3.3.2.3.
By Application
10.3.3.2.4.
By End User
11. Middle East and
Africa Formulation Development Outsourcing Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1. By Services (Pre-Formulation
Services v/s Formulation Optimization)
11.2.1.1. By Pre-Formulation
Services (Discovery & Preclinical Services v/s Analytical Services)
11.2.1.2. By Formulation
Optimization (Phase I, Phase II, Phase III, Phase IV)
11.2.2. By Dosage Form
(Oral, Topical, Intravenous, Others)
11.2.3. By Application (Oncology,
Genetic Disorders, Neurology, Infectious Diseases, Respiratory, Cardiovascular,
Others)
11.2.4. By End User (Pharmaceutical
& Biopharmaceutical Companies, Governments, Academic & Research Institutions,
Others)
11.2.5.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Formulation Development Outsourcing Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Services
11.3.1.2.2.
By Dosage Form
11.3.1.2.3.
By Application
11.3.1.2.4.
By End User
11.3.2.
UAE Formulation Development Outsourcing Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Services
11.3.2.2.2.
By Dosage Form
11.3.2.2.3.
By Application
11.3.2.2.4.
By End User
11.3.3.
Saudi Arabia Formulation Development Outsourcing Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Services
11.3.3.2.2.
By Dosage Form
11.3.3.2.3.
By Application
11.3.3.2.4.
By End User
11.3.4.
Kuwait Formulation Development Outsourcing Market Outlook
11.3.4.1.
Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2.
Market Share & Forecast
11.3.4.2.1.
By Services
11.3.4.2.2.
By Dosage Form
11.3.4.2.3.
By Application
11.3.4.2.4.
By End User
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends &
Developments
14. Competitive
Landscape (Inclusive of SWOT Analysis)
14.1.
Charles River
Laboratories International, Inc.
14.2.
Catalent Inc.
14.3.
Quotient Bioresearch
Ltd.
14.4.
Aizant Drug Research
Solutions Private Limited
14.5.
Laboratory
Corporation of America Holdings
14.6.
Syngene
International Ltd
14.7.
Irisys LLC
14.8.
Intertek Group plc
14.9.
Piramal Pharma
Limited
14.10.
Emergent
BioSolutions Inc.
14.11.
Lonza Group AG
14.12.
Dr. Reddy's
Laboratories Ltd
14.13.
Thermo Fischer
Scientific, Inc. (Patheon)
14.14.
PCI Pharma Services
14.15.
Hermes Pharma
15.
Strategic
Recommendations
16.
About Us &
Disclaimer